BQR-695

1513879-21-4

352.39

DMSO : 50 mg/mL (141.89 mM; Need ultrasonic); H2O : < 0.1 mg/mL (insoluble)

PI3K/Akt/mTOR; Anti-infection

BQR-695 is a PI4KIIIbeta inhibitor with IC₅₀s of 80 and 3.5 nM for human PI4KIIIbeta and Plasmodium variant of PI4KIIIbeta, respectively. IC50 & Target: IC50: 80 nM (human PI4KIIIbeta), 3.5 nM (Plasmodium PI4KIIIbeta)^[1] In Vitro: Treatment with 0.5 uM of either KAI407 or BQR695 causes GFP-PH^Osh2 to redistribute to the parasite plasma membrane, consistent with depletion of intracellular PI4P upon inhibition of PfPI4K function. BQR695 shows no evidence of toxicity against mature red blood cells (RBCs), induces a schizont-stage arrest indistinguishable from that observed in imidazopyrazine-treated parasites and exhibits cross-resistance with the imidazopyrazine-resistant lines^[2].